FGF19 siRNA_Lentivectors
- Known as:
- FGF19 siRNA_Lentivectors
- Catalog number:
- i007902a
- Product Quantity:
- 500ng
- Category:
- -
- Supplier:
- ABM
- Gene target:
- FGF19 siRNA_Lentivectors
Related genes to: FGF19 siRNA_Lentivectors
- Gene:
- FGF19 NIH gene
- Name:
- fibroblast growth factor 19
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-06
- Date modifiied:
- 2016-10-05
Related products to: FGF19 siRNA_Lentivectors
Related articles to: FGF19 siRNA_Lentivectors
- Penile squamous cell carcinoma (PSCC) is a rare malignancy with limited genomic data in Asian populations. Lymph node metastasis heavily dictates prognosis, yet molecular determinants of progression remain poorly understood. We aimed to characterize the genomic landscape and explore candidate prognostic genomic features using paired primary and metastatic PSCC tumors. - Source: PubMed
Publication date: 2026/08/27
Lou KexinLiang LinghuiCai HongzhouXu TingWang FufengWang DiJing QifanYin Jiani CZhang XiaoxiangXu Zicheng - Hepatic ischemia-reperfusion injury (HIRI) is a major cause of graft dysfunction and postoperative complications following liver transplantation and hepatic resection. Increasing evidence indicates that the gut-liver axis plays a central role in modulating hepatic injury, inflammation, and tissue regeneration during HIRI. - Source: PubMed
Publication date: 2026/08/26
de Oliveira Thiago Henrique CaldeiraGonçalves Gleisy Kelly Neves - Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC. - Source: PubMed
Publication date: 2026/08/25
Tran Nguyen HPalmer Mathias EUlrich AngelaMcCue Shaylene AMahipal AmitMa Wen WeeBabiker Hani MMajeed UmairHalfdanarson Thorvardur RMcWilliams Robert RJin ZhaohuiCarr RyanKankeu Fonkoua Lionel AurelienWashburn LeslieConboy CaitlinGraham Rondell PTorbenson MichaelStarlinger PatrickJethwa Krishan RHallemeier ChristopherRevzin AlexanderThompson Scott MGoenka Ajit HVenkatesh Sudhakar KSonbol Mohamad BBorad Mitesh JBekaii-Saab TaniosGores Gregory JRoberts Lewis RHeimbach Julie KOu Fang-Shu - Fibroblast growth factor 19 (FGF19) signaling is a promising therapeutic target for metabolic diseases and cancers, and several agents targeting the FGF19 signaling are currently undergoing clinical trials. However, as an endocrine FGF, FGF19's organism-wide functions remain vague, which hinders the advancing of FGF19 signaling-based therapies. To systematically explore its systemic effects, we performed a multi-tissue transcriptomic profiling in an FGF19 knock-in mouse model. Sustained FGF19 exposure induced extensive, tissue‑specific transcriptional reprogramming. For instance, lipid metabolic pathways were broadly altered not only in canonical metabolic organs, but also in immune‑related tissues including the spleen and thymus. Furthermore, integrated analysis and functional validation demonstrated that FGF19 promoted monocyte/macrophage (Mo/MΦ) migration in an FGFR4‑involved manner, associated with an M2-like polarization state. Moreover, we developed a macrophage‑targeted sustained‑release FGF19 delivery system, which significantly accelerated wound healing and enhanced M2 macrophage infiltration in a murine full‑thickness skin injury model. Overall, our study establishes a multi‑tissue transcriptional atlas of FGF19 action, reveals broad metabolic and immune regulatory responses to sustained human FGF19 exposure in mice, and provides a targeted therapeutic strategy for modulating macrophage. - Source: PubMed
Publication date: 2026/08/22
Xiao YangKuang LiwenHe JuanLiu XudongYi YiSong MiaoyuXia JieZhou YuLei JuanChen YuLiu XiChen JiongmingChen YijiaoZeng XianghuaLi YongshengZhao Huakan - Anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have revolutionized the treatment for HER2-positive and HER2-low metastatic breast cancer (MBC). However, the comparative efficacy, safety, and molecular predictors of response to various anti-HER2 ADCs remain limited. - Source: PubMed
Publication date: 2026/08/20
Gui XiujuanChen HaizhuZhao JianliLai HongnaLuo SiminChai JieCai YangyangWu WenjingZeng YinduoChen MaojianWang YingYao HeruiDing Linxiaoxiao